LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

NCT05990465 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Non Hodgkin Lymphoma
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Burkitt Lymphoma

Interventions

DRUG: Pirtobrutinib
DRUG: LV20.19 CAR T cells

Sponsor

Medical College of Wisconsin